Celcuity Inc. (CELC) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $130.21: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 28%; Elevated put/call ratio: 2.09; Below-average business quality.
Celcuity is a clinical-stage biotech with one lead asset, gedatolisib (a pan-PI3K/mTOR inhibitor), in Phase 3 VIKTORIA-1 for HR+/HER2- advanced breast cancer; NDA accepted by FDA with PDUFA date of July 17, 2026. Phase 3 VIKTORIA-2 ongoing; no revenue; $338.8M indebtedness as of... Read more
Sell if holding. Engine safety override at $130.21: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 28%; Elevated put/call ratio: 2.09; Below-average business quality. Chart setup: RSI 58 mid-range, Bollinger mid-band. Score 5.0/10, moderate confidence.
Passes 8/10 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.80, news boost analyst cluster(3), earnings proximity 86d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Celcuity Inc.
Latest news
- HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $185 — benzinga May 18, 2026 positive
- Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst — benzinga May 15, 2026 positive
- Wells Fargo Maintains Overweight on Celcuity, Raises Price Target to $183 — benzinga May 15, 2026 positive
- Needham Reiterates Buy on Celcuity, Maintains $157 Price Target — benzinga May 15, 2026 positive
- Transcript: Celcuity Q1 2026 Earnings Conference Call — benzinga May 14, 2026 neutral
Generated 2026-05-20T21:56:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Volatile — 7.5% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $130.21: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 28%; Elevated put/call ratio: 2.09; Below-average business quality. Chart setup: RSI 58 mid-range, Bollinger mid-band. Prior stop was $120.30. Score 5.0/10, moderate confidence.
Take-profit target: $145.29 (+12.3% upside). Prior stop was $120.30. Stop-loss: $120.30.
Quality below floor (1.8 < 4.0).
Celcuity Inc. trades at a P/E of N/A (forward 178.6). TrendMatrix value score: 4.0/10. Verdict: Sell.
18 analysts cover CELC with a consensus score of 4.3/5. Average price target: $167.
What does Celcuity Inc. do?Celcuity is a clinical-stage biotech with one lead asset, gedatolisib (a pan-PI3K/mTOR inhibitor), in Phase 3...
Celcuity is a clinical-stage biotech with one lead asset, gedatolisib (a pan-PI3K/mTOR inhibitor), in Phase 3 VIKTORIA-1 for HR+/HER2- advanced breast cancer; NDA accepted by FDA with PDUFA date of July 17, 2026. Phase 3 VIKTORIA-2 ongoing; no revenue; $338.8M indebtedness as of Dec 31, 2025 from equity and convertible notes.